Q2 Earnings Round-Up Part 2: Launches, Growth Still Face Challenges
Executive Summary
The pandemic created a tough environment for sales of both newly launched products and growing products, especially for small-to-medium enterprises. Scrip reviewed the second quarter earnings calls for several SMEs: some are continuing to feel pressure, and some are starting to recover. [See Part 1 for companies reporting a turnaround.]
You may also be interested in...
Jazz Hopes Pediatric Vaccinations Can Speed Epidiolex Uptake
The pandemic has dampened the seizure drug’s sales, but the company is hoping to see a pickup as an expanding patient base could help it achieve anticipated blockbuster sales.
Finance Watch: Four New IPOs Hold Steady In First Days Of Trading
Public Company Edition: Xilio, Ventyx, MiNK and Context went public in the US and later traded at or above their initial public offering prices. Also, Sarepta raised $500m and Relay grossed $350m in new offerings, while Oncopeptides, Esperion, Zymergen and Ardelyx reorganized and cut jobs.
Proteome-Focused ProFound Emerges From Flagship Pioneering
The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.